Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Steven E. Coutre, MD, Ian Flinn, Marshall T. Schreeder, MD, Nathan Fowler, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Kanti R. Rai, MD, Thomas E Boyd, MD, Richard R. Furman, MD, Leanne M. Holes, Yeonhee Kim, PhD, Wayne R. Godfrey, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3063.

https://doi.org/10.1182/blood.V124.21.3063.3063

Published: 2014

Journal Articles

Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD PhD, Ian W. Flinn, MD PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD, Gilles Andre Salles, MD PhD

Blood (2014) 124 (21): 1708.

https://doi.org/10.1182/blood.V124.21.1708.1708

Published: 2014

Journal Articles

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven E. Coutre, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert Yu, Wayne R. Godfrey, Nina D. Wagner-Johnston

Blood (2014) 123 (22): 3398–3405.

https://doi.org/10.1182/blood-2013-11-537555

Published: 2014

Journal Articles

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard, Richard R. Furman, Jennifer R. Brown, John C. Byrd, Nina D. Wagner-Johnston, Steve E. Coutre, Don M. Benson, Sissy Peterman, Yoonjin Cho, Heather K. Webb, David M. Johnson, Albert S. Yu, Roger G. Ulrich, Wayne R. Godfrey, Langdon L. Miller, Stephen E. Spurgeon

Blood (2014) 123 (22): 3406–3413.

https://doi.org/10.1182/blood-2013-11-538546

Published: 2014

Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Blood (2013) 122 (21): 85.

https://doi.org/10.1182/blood.V122.21.85.85

Published: 2013

Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD

Blood (2012) 120 (21): 3645.

https://doi.org/10.1182/blood.V120.21.3645.3645

Published: 2012

Journal Articles

CD4 + CD25 + regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy

Lequn Li, Wayne R. Godfrey, Stephen B. Porter, Ying Ge, Carle H. June, Bruce R. Blazar, Vassiliki A. Boussiotis

Blood (2005) 106 (9): 3068–3073.

https://doi.org/10.1182/blood-2005-04-1531

Published: 2005

Journal Articles

Cord blood CD4 + CD25 + -derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function

Wayne R. Godfrey, Darrin J. Spoden, Ying G. Ge, Seth R. Baker, Baoling Liu, Bruce L. Levine, Carl H. June, Bruce R. Blazar, Stephen B. Porter

Blood (2005) 105 (2): 750–758.

https://doi.org/10.1182/blood-2004-06-2467

Published: 2005

Journal Articles

Cord Blood CD4+CD25+ Derived T Regulatory Cell Lines Express FoxP3 Protein and Manifest Potent Suppressor Function.

Wayne R. Godfrey, MD, Darrin J. Spoden, Ying G. Ge, Seth R. Baker, Baoling Liu, Bruce L. Levine, PhD, Carl H. June, MD, Bruce R. Blazar, MD, Stephen B. Porter

Blood (2004) 104 (11): 2124.

https://doi.org/10.1182/blood.V104.11.2124.2124

Published: 2004

Journal Articles

CD4 + CD25 + Regulatory T Cells from Cord Blood Have Functional and Molecular Properties of T Cell Anergy.

Lequn Li, MD, PhD, Wayne R. Godfrey, MD, Stephen B. Porter, Ying Ge, Carle H. June, MD, Bruce R. Blazar, MD, Vassiliki A. Boussiotis, MD, PhD

Blood (2004) 104 (11): 316.

https://doi.org/10.1182/blood.V104.11.316.316

Published: 2004

Journal Articles

In vitro–expanded human CD4 + CD25 + T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures

Wayne R. Godfrey, Ying G. Ge, Darrin J. Spoden, Bruce L. Levine, Carl H. June, Bruce R. Blazar, Stephen B. Porter

Blood (2004) 104 (2): 453–461.

https://doi.org/10.1182/blood-2004-01-0151

Published: 2004

Journal Articles

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation

Wayne R. Godfrey, Mark R. Krampf, Patricia A. Taylor, Bruce R. Blazar

Blood (2004) 103 (3): 1158–1165.

https://doi.org/10.1182/blood-2003-04-1098

Published: 2004

NARROW

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

CD4 + CD25 + regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy

Cord blood CD4 + CD25 + -derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function

Cord Blood CD4+CD25+ Derived T Regulatory Cell Lines Express FoxP3 Protein and Manifest Potent Suppressor Function.

CD4 + CD25 + Regulatory T Cells from Cord Blood Have Functional and Molecular Properties of T Cell Anergy.

In vitro–expanded human CD4 + CD25 + T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only